EVI2A is a transmembrane protein located within intron 27b of the NF1 tumor suppressor gene on chromosome 17.2 1. The protein functions as part of a cell-surface receptor, likely complexing with itself and/or other proteins within the membrane 1. EVI2A demonstrates significant roles in multiple cancer types. In kidney renal clear cell carcinoma, elevated EVI2A expression correlates with advanced tumor stage, poor survival outcomes (AUC=0.906 for diagnostic accuracy), and associations with immune checkpoint activation 2. In pancreatic adenocarcinoma, EVI2A promotes gemcitabine resistance through the SMYD2-H3K36me2 epigenetic axis while suppressing T cell effector activation and promoting M2 macrophage-mediated immune evasion 3. Similarly, in osteosarcoma, high EVI2A expression predicts poor prognosis and activates the MEK/ERK signaling pathway to enhance cell proliferation and migration 4. Mendelian randomization analysis identified EVI2A as causally associated with endometrial cancer risk 5. EVI2A may also have roles in neurofibromatosis type 1-related tumorigenesis and leukemia 6. These findings establish EVI2A as a promising biomarker and therapeutic target across multiple malignancies.